KK
URGN icon

KLP Kapitalforvaltning’s UroGen Pharma URGN Stock Holding History

KLP Kapitalforvaltning’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$375K Sell
10,200
-4,100
-29% -$111K ﹤0.01% 1642
2026
Q1 		$257K Buy
+14,300
New +$287K ﹤0.01% 1718
2025
Q1 		– Sell
-5,500
Closed -$58.6K – 2295
2024
Q4 		$58.6K Buy
+5,500
New +$65.8K ﹤0.01% 2217

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

KLP Kapitalforvaltning's URGN Position: Q2 2026 in Review

KLP Kapitalforvaltning reduced its UroGen Pharma (URGN) stake by 29% in Q2 2026, selling an estimated $111K and leaving 10,200 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #1642.

KLP Kapitalforvaltning first reported a position in URGN in Q4 2024 and has held it in 3 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • KLP Kapitalforvaltning held 10,200 shares of UroGen Pharma worth $375K as of Q2 2026.
  • KLP Kapitalforvaltning sold 4,100 UroGen Pharma shares in Q2 2026, an estimated $111K.
  • UroGen Pharma made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1642 holding.
  • KLP Kapitalforvaltning first reported a position in UroGen Pharma in Q4 2024 and has held it in 3 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.